Excretion of 2,3-dihydroxy-propionamide (OH-PA), the hydrolysis product of glycidamide, in human urine after single oral dose of deuterium-labeled acrylamide.
A dose of 0.99 mg d(3)-acrylamide (d(3)-AA) (13.2 μg/kg body weight) was ingested by a healthy male volunteer. Urine samples were collected over a period of 46 h after the intake and analyzed for the hydrolysis product of glycidamide (GA), 2,3-dihydroxy-propionamide (OH-PA), a metabolite of the toxicologically relevant oxidative AA metabolism pathway; 5.4% of the administered d(3)-AA dose was eliminated as OH-PA within 46 h after ingestion. Therefore, OH-PA represents a major metabolite of the oxidative metabolism pathway. Elimination kinetics of OH-PA is similar to the oxidative metabolites N-acetyl-S-(2-carbamoyl-2-hydroxyethyl)-cysteine (GAMA) and N-acetyl-S-(1-carbamoyl-2-hydroxyethyl)-cysteine (iso-GAMA). The major excretion of d(3)-OH-PA took place between 8 and 22 h with the highest urinary d(3)-OH-PA concentration (c (max)) of 69.3 μg/L urine, 18 h (t (max)) postdose. OH-PA (5.4%), together with the other known urinary metabolites of the oxidative pathway GAMA (4.6%) and iso-GAMA (0.8%), represents 10.8% of the total AA dose. The share of the oxidative pathway metabolites is much smaller than the share of the reductive pathway metabolite N-acetyl-S-(2-carbamoylethyl)-cysteine (AAMA) that represents 51.7% of the ingested d(3)-AA dose. However, this new quantitative human data on OH-PA together with the previous data on the other oxidative pathway metabolites are of special importance when evaluating the carcinogenic potential of AA and when comparing human data with data from animal studies.
Institute and Outpatient Clinic of Occupational, Social and Environmental Medicine, University of Erlangen-Nürnberg, Schillerstr. 25/29, 91054, Erlangen, Germany.
Eva C
EC
Hartmann
Julia M
JM
Latzin
Birgit K
BK
Schindler
Holger M
HM
Koch
Jürgen
J
Angerer
D000081:Acetamides; D000111:Acetylcysteine / Q000031:analogs & derivatives / Q000652:urine; D020106:Acrylamide / Q000493:pharmacokinetics*; D000328:Adult; D000577:Amides / Q000737:chemistry / Q000652:urine*; D053000:Analytic Sample Preparation Methods; D002273:Carcinogens / Q000493:pharmacokinetics*; D003545:Cysteine / Q000031:analogs & derivatives / Q000652:urine; D003903:Deuterium; D004852:Epoxy Compounds / Q000378:metabolism*; D005463:Fluoroacetates; D008401:Gas Chromatography-Mass Spectrometry; D006801:Humans; D006868:Hydrolysis; D007202:Indicators and Reagents / Q000737:chemistry; D008297:Male; D017646:Organosilicon Compounds / Q000737:chemistry; D010084:Oxidation-Reduction; D012821:Silanes / Q000737:chemistry; D013454:Sulfoxides / Q000652:urine; D014269:Trifluoroacetic Acid / Q000737:chemistry
C561481:2,3-dihydroxypropionamide; D000081:Acetamides; D000577:Amides; D002273:Carcinogens; D004852:Epoxy Compounds; D005463:Fluoroacetates; D007202:Indicators and Reagents; C543946:N-acetyl-S-(1-carbamoyl-2-hydroxy-ethyl)-L-cysteine; C561482:N-acetyl-S-(2-carbamoylethyl)cysteine-sulfoxide; C103739:N-acetyl-S-(N-(2-hydroxyethyl)carbamoylmethyl)cysteine; D017646:Organosilicon Compounds; D012821:Silanes; D013454:Sulfoxides; C024004:t-butyldimethylchlorosilane; D020106:Acrylamide; C071834:glycidamide; C059151:N-methyl-N-(tert-butyldimethylsilyl)trifluoroacetamide; D003903:Deuterium; D014269:Trifluoroacetic Acid; D003545:Cysteine; D000111:Acetylcysteine